SCHEMBL17453073

SCHEMBL17453073

CC(C)c1ccc2nn(CC(C)(C)O)cc2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
SCN4A P35499 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TYR P14679 1/20 0.33
IRAK4 Q9NWZ3 7/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
CACNA1G O43497 1/20 0.32
CACNA1H O95180 1/20 0.32
CACNA1I Q9P0X4 1/20 0.32
PDE10A Q9Y233 1/20 0.32
POLB P06746 2/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
BRD4 O60885 1/20 0.31
EGLN1 Q9GZT9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24352977 0.84 NPC1 (0.35) NPC1RAB9ASCN4ASMN1; SMN2TYR
SCHEMBL17448068 0.81 KLKB1 (0.37) IRAK4PDE10AMEN1ALDH1A1KMT2A
SCHEMBL22020836 0.80 NPC1 (0.38) NPC1RAB9ASCN4ASMN1; SMN2TYR
SCHEMBL26983072 0.79 HDAC8 (0.38) NPC1RAB9ASMN1; SMN2IRAK4PDE10A
SCHEMBL24352978 0.77 CYP17A1 (0.34) NPC1RAB9ASCN4ASMN1; SMN2TYR
SCHEMBL24352976 0.77 CYP17A1 (0.34) NPC1RAB9ASCN4ASMN1; SMN2TYR
SCHEMBL23638519 0.77 NPC1 (0.39) NPC1RAB9ASCN4ASMN1; SMN2TYR
SCHEMBL26482450 0.77 NPC1 (0.36) NPC1RAB9ASCN4ASMN1; SMN2TYR
SCHEMBL29110339 0.76 NPC1 (0.42) NPC1RAB9ASMN1; SMN2IRAK4POLB
SCHEMBL29985602 0.75 TLR7 (0.40) IRAK4PDE10AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160016951-A1 NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS MERCK PATENT GMBH (DE) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016951-A1 NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS CDK8, CDK9, CDK18 NPC1 2613/4885RAB9A 1009/4885SCN4A 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.